Please login to the form below
PsiOxus Therapeutics
This page shows the latest PsiOxus Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Bristol-Myers Squibb acquires Cormorant for $520m
That project will look at the safety and efficacy of enadenotucirev - which is made by PsiOxus Therapeutics in Oxford, UK - in combination with Opdivo for the treatment of a range of
Latest news
-
BMS to explore new options for its immuno-oncology drug Opdivo
The company will work with PsiOxus Therapeutics to evaluate the safety and efficacy of the Oxford, UK biotech's enadenotucirev in combination with Opdivo for the treatment of a range of ... BMS has agreed to an upfront payment of $10m to PsiOxus, with
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
25 Women Leaders in UK Healthcare
The new wave of healthcare has to start to bring diagnostics, devices and therapeutics together. ... Before she joined Crescendo, she held industry and corporate finance roles with private and listed SMEs, including PsiOxus Therapeutics, MISSION
-
Deal Watch December 2016
995+. PsiOxus Therapeutics (UK). BMS (US). Licence. NG-348: preclinical “armed” oncolytic virus targeting tumour cells. ... and Bicycle Therapeutics at $1bn, and the Purdue Pharma-Exicure deal, at $790m.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Crescendo Biologics appoints CFO
She joins from PsiOxus Therapeutics where she served as chief financial officer, and has also held a number of positions at Cytomyx Holdings, OrthoMimetics, and Mission Therapeutics. ... ambitious plans to create a high value pipeline of differentiated
-
Paolo Paoletti named as executive chairman of Kesios
Paoletti was formerly president of GSK Oncology. Imperial Innovations Group has appointed Dr Paolo Paoletti as executive chairman of portfolio company Kesios Therapeutics. ... Paoletti is additionally a non-executive director of PsiOxus Therapeutics,
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Sanofi and AI specialist Aqemia enter $140m drug discovery partnership
- Novartis’ Fabhalta approved by FDA as first oral monotherapy for rare blood disease PNH
- Merck gains rights to Abbisko’s pimicotinib in deal worth over $70m
- Almirall, BSC and Nostrum Biodiscovery partner for dermatological diseases
- LifeArc launches £5m motor neurone disease drug repurposing programme
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
No results were found
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
